Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy

Immune checkpoint therapy, such as programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blockade, has achieved remarkable results in treating various tumors. However, most cancer patients show a low response rate to PD-1/PD-L1 blockade, especially those with microsatellite stable/m...

Full description

Bibliographic Details

Published in:	Research
Main Authors:	Shengbo Sun, Jingxin Ma, Tingting Zuo, Jinyao Shi, Liting Sun, Cong Meng, Wenlong Shu, Zhengyang Yang, Hongwei Yao, Zhongtao Zhang
Format:	Article
Language:	English
Published:	American Association for the Advancement of Science (AAAS) 2024-01-01
Online Access:	https://spj.science.org/doi/10.34133/research.0488